ArticleFrontiers in pharmacology2026
Simulating an intravenous-to-oral cefotaxime-to-cefditoren/cefuroxime switch: an
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The lack of oral equivalent for third-generation IV cephalosporins challenges sequential cephalosporin therapy for pneumococcal infections. This Methods: We used an Results: Against strain 1S, both oral cephalosporins sustained bactericidal activity in the model, similar to the complete CTX-IV regimen. For strain 2S, CTX-to-CDN maintained bactericidal efficacy comparable to CTX-IV, while CTX-to-CXM showed with counts at 36 h similar to initial inoculum. Against strain 3I, CTX-to-CDN exhibited a bacteriostatic effect, whereas CTX-to-CXM was equivalent to the growth control. Strain 4I was associated with regrowth in both sequential regimens. The CTX-IV regimen was bacteriostatic against strains 3I and 4I. Discussion: Overall, despite the limitations of the proposed model in reproducing the antimicrobial activity of agents with high plasma protein binding, such as CDN, greater
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.